Molecular docking studies indicated that empagliflozin's binding affinity with key genes such as DGAT1, TYMS, and PTGS2 presents a novel therapeutic avenue for NAFLD-associated AF. Here, PTGS2 is linked to metabolic dysfunction-associated steatotic liver disease.